Meyer Handelman Co. Has $41.33 Million Stake in Gilead Sciences, Inc. $GILD

Meyer Handelman Co. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 336,724 shares of the biopharmaceutical company’s stock after selling 10,645 shares during the period. Gilead Sciences accounts for approximately 1.3% of Meyer Handelman Co.’s investment portfolio, making the stock its 21st biggest position. Meyer Handelman Co.’s holdings in Gilead Sciences were worth $41,330,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Csenge Advisory Group increased its position in shares of Gilead Sciences by 319.0% during the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after buying an additional 16,288 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in Gilead Sciences by 52.1% during the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock worth $8,713,000 after buying an additional 26,882 shares during the last quarter. Cookson Peirce & Co. Inc. lifted its holdings in Gilead Sciences by 249.1% in the third quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock valued at $1,115,000 after buying an additional 7,168 shares during the period. Railway Pension Investments Ltd boosted its position in Gilead Sciences by 3.1% during the third quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after acquiring an additional 42,200 shares during the last quarter. Finally, TriaGen Wealth Management LLC bought a new stake in Gilead Sciences during the third quarter valued at $1,274,000. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Mizuho lifted their price objective on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Wall Street Zen upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 14th. Argus raised their target price on Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Finally, UBS Group increased their price target on Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Twenty-four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $157.62.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, March 16th. The shares were sold at an average price of $144.23, for a total value of $432,690.00. Following the completion of the sale, the insider owned 131,779 shares of the company’s stock, valued at approximately $19,006,485.17. This trade represents a 2.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at $1,101,620. This trade represents a 35.92% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 299,280 shares of company stock worth $42,820,550. Insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $139.37 on Wednesday. The firm has a market capitalization of $172.99 billion, a P/E ratio of 20.59, a P/E/G ratio of 1.79 and a beta of 0.37. The firm’s 50-day moving average price is $144.62 and its 200-day moving average price is $129.06. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same period last year, the business posted $1.90 EPS. The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend was Friday, March 13th. Gilead Sciences’s payout ratio is 48.45%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.